Finding brain markers for suicide prevention treatments
Part of Mental health clinical trials.
This study looks for signs in your blood or brain that can help doctors predict how well certain depression and suicide treatments will work. You might participate if you are already planning to have ECT, ketamine, or esketamine as part of your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have a diagnosis of major depressive disorder or bipolar disorder
- You have significant suicidal thoughts or behaviors
- You are scheduled to receive ECT, IV ketamine, or esketamine nasal spray as part of your regular care
- You are able to have an MRI scan and do not have a neurological disorder
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how ketamine affects the brain in people dealing with suicidal thoughts or an active suicide crisis. It uses questionnaires, consent testing, and brain imaging to look for biological changes that may relate to symptom improvement.
This study looks at how certain brain “inhibitory” signals work in teenagers and young adults who have depression and either suicide thoughts or past suicide behavior. The goal is to better understand suicide risk and what might help reduce it, using brain and brainwave testing.
This trial compares two treatments—ECT (electroconvulsive therapy, which uses electrical stimulation) and ketamine (a medicine given as a shot)—to see which works better for quickly reducing suicidal depression. It is for adults who are in a severe depressive episode with active suicidal thoughts.
This Phase 4 study tests whether ongoing treatment with ketamine or esketamine can reduce suicidal thoughts in people with major depression who are at high risk. Because the study focuses on long-term maintenance, you’d receive treatment over time while being closely monitored for safety and mental health changes.
This study tests a new type of brain stimulation called TMS (transcranial magnetic stimulation) for young people ages 15-25 who are having serious depression and suicidal thoughts. The goal is to see if this treatment can help reduce risk and improve mood.
This study uses a blood test (biomarker) to help pick the antidepressant that might work best for you. It compares two treatments—standard antidepressants and ketamine—in people with major depression who haven't gotten enough relief from one prior treatment.
Hear when a new Suicidal Thoughts and Behaviors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.